| Generic Name |
Palonosetron Hydrochloride Injection |
| Strength |
0.25mg/5ml |
| Packing |
1vial/box |
| Origin |
China |
Component:
Palonosetron Hydrochloride
Character:
This product is a colorless clear liquid.
Indications:
Prevent acute nausea and vomiting caused by moderate and severe emetic chemotherapy.
Usage and dosage:
The recommended dose is: about 30 minutes before chemotherapy, a single dose of palonosetron 0.25mg intravenous injection time of more than 30 seconds.
Matters needing attention:
Allergic reactions may occur in individuals allergic to other selective 5-HT3 receptor antagonists.
At dose levels studied in foreign clinical trials, palonosetron has not been observed to cause clinically meaningful QTc interval prolongation. The effect of palonosetron on the QTc interphase was evaluated in a double-blind, randomized, parallel, placebo-controlled and position-controlled (moxifloxacin) complete QT/QTc study in 221 healthy adult male and female volunteers. No effect on QTc interval or other ECGs was observed at 0.25, 0.75, or 2.25mg doses, and no clinically significant changes in heart rate, atrioventricular conduction, and cardiac repolarization were observed. However, based on information about the use of other 5-HT3 receptor antagonists, palonosetron should be used with caution in patients who are concomitant with QT prolongation and who have or may develop QR interval prolongation. These patients include: people with hypokalemia or hypomagneemia, people with electrolyte abnormalities due to diuretic drug use information, people with congenital long QT syndrome, people taking antiarrhythmic drugs or other drugs that can cause QT interval prolongation, and people treated with cumulative high doses of anthracyclines.
Palonosetron hydrochloride injection cannot be mixed with other drugs, so normal saline should be used to flush the infusion line before and after Palonosetron injection.
Audited Supplier 
){kind=link}
){kind=link}